Senfina’s technology provides the means to evaluate many drugs and genetic drug targets for the impact on lifespan and quality of life through behavioral observations, while simultaneously proving information on molecular response of target pathways through fluorescent imaging in the same animals. Single-animal culture systems allow the same individual animals to be tracked over the course of their lifespan, enabling molecular processes to be connected to health outcomes as single-animal resolution. This simultaneous collection of multi-dimensional information enables these evaluations to be conducted in a cost-effective, timely, and scalable fashion.
Longevity biotechnology is a growing market driven by an increasingly older population and the accelerating prevalence of age-associated diseases. An increasing decline of cognitive and muscular abilities of particular prominence and well-suited to study in C. elegans. This technology opens ways for the differential monitoring of these developments in tens to hundreds of thousands of individuals at single-animal resolution.
Due to the increasing lifespan of humans, the age-related degenerative diseases and the need for their management are on the rise. The Longevity and Anti-Senescence Therapy Market is currently around $26B with an anticipated annual growth of about 6.5%.